Readout LOUD podcast: Biotech’s 12 months in assessment

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the publication Adam’s Biotech Scorecard. You possibly can attain Adam on Sign at stataf.54.

Is the biotech trade actually out of its hunch? Why are employers dropping protection of weight reduction medication? And what is going to the hosts bake for the vacations?

We focus on all that and extra on this week’s episode of “The Readout LOUD,” the final episode of the 12 months. We carry on Bruce Sales space, companion at enterprise capital agency Atlas Enterprise, to mirror on every little thing that’s occurred within the biotech trade this 12 months and to look forward on the developments subsequent 12 months.

We additionally chat about Adam’s picks for finest and worst biopharma CEOs in 2025, and why Eli Lilly and Novo Nordisk’s direct-to-consumer choices could also be contributing to employers’ selections to drop protection of weight reduction medication.

To learn extra on Adam’s picks for finest CEOs, go right here; for extra on his choose for worst CEO, go right here; and for extra on employers dropping protection of weight reduction medication, go right here.

Make sure to enroll in “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.